Valuation: SurModics

Market Cap 427M 370M 347M 317M 596M 40.79B 605M 4.09B 1.6B 20.42B 1.6B 1.57B 68.11B P/E 2023
-292x
P/E 2024 -47.3x
Enterprise Value 420M 364M 342M 312M 586M 40.13B 596M 4.02B 1.57B 20.09B 1.58B 1.54B 67.01B EV / Sales 2023
3.33x
EV / Sales 2024 4.33x
Free-Float
99.63%
Yield 2023 *
-
Yield 2024 -
1 year 25.87
Extreme 25.87
43
3 years 25.17
Extreme 25.17
43
5 years 16
Extreme 16
62.27
10 years 16
Extreme 16
82.35
Manager TitleAgeSince
Chief Executive Officer 67 2025-11-18
Director of Finance/CFO 53 2025-11-18
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 2025-11-18
Director/Board Member 53 2025-11-18
Date Insider Type Main position Quantity % Market Cap.
11/19/25 Issuer sale

Director

35,847 0.2507%
11/19/25 Issuer sale

Controller/Auditor

24,311 0.1700%
11/19/25 Issuer sale

Director

51,877 0.3628%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-.--%+13.34%+15.57% 615M
+0.32%+3.07%-14.01%+4.87% 192B
-0.20%+5.42%-2.51%+8.92% 116B
-1.32%-4.62%+6.52%+65.22% 59.95B
+2.11%+2.55%+34.34%+62.10% 54.64B
-0.88%+2.77%-7.14%-35.62% 50B
+0.75%+10.19%+14.41%-20.97% 34.26B
+0.23%+3.10% - - 31.15B
-1.74%-0.70%+40.59%-13.44% 24.79B
+0.85%+14.53%-3.89%+20.23% 24.07B
Average +0.07%+3.81%+9.07%+11.88% 58.76B
Weighted average by Cap. +0.13%+4.27%+0.62%+12.47%

Financials

2023 2024
Net sales 133M 115M 108M 98.23M 185M 12.65B 188M 1.27B 495M 6.33B 498M 487M 21.13B 126M 109M 102M 93.41M 176M 12.03B 179M 1.21B 471M 6.02B 473M 463M 20.09B
Net income -1.54M -1.33M -1.25M -1.14M -2.14M -147M -2.18M -14.7M -5.74M -73.38M -5.77M -5.64M -245M -11.54M -10M -9.38M -8.55M -16.09M -1.1B -16.35M -110M -43.11M -551M -43.33M -42.39M -1.84B
Net Debt -12.1M -10.49M -9.83M -8.97M -16.87M -1.15B -17.14M -116M -45.2M -578M -45.43M -44.45M -1.93B -6.87M -5.95M -5.58M -5.09M -9.58M -656M -9.73M -65.73M -25.66M -328M -25.79M -25.23M -1.09B
Logo SurModics
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Employees
389
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SRDX Stock